Enozertinib

N/A

Report date: 2025/05/26 16:59:22
NME

Base Information

Drug NameEnozertinib
Drug Alias NameORIC-114VRN-07
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVoronoi Inc
China Registration ClassN/A

Develop Information

Active CompaniesVoronoi IncOric Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A